Citius Pharmaceuticals, Inc. (CTXR): Price and Financial Metrics


Citius Pharmaceuticals, Inc. (CTXR): $0.90

0.00 (-0.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CTXR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CTXR Stock Price Chart Interactive Chart >

Price chart for CTXR

CTXR Price/Volume Stats

Current price $0.90 52-week high $4.56
Prev. close $0.91 52-week low $0.86
Day low $0.89 Volume 265,111
Day high $0.91 Avg. volume 1,692,354
50-day MA $1.30 Dividend yield N/A
200-day MA $1.65 Market Cap 132.07M

Citius Pharmaceuticals, Inc. (CTXR) Company Bio


Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.


CTXR Latest News Stream


Event/Time News Detail
Loading, please wait...

CTXR Latest Social Stream


Loading social stream, please wait...

View Full CTXR Social Stream

Latest CTXR News From Around the Web

Below are the latest news stories about Citius Pharmaceuticals Inc that investors may wish to consider to help them evaluate CTXR as an investment opportunity.

Maxim Group Thinks Citius Pharmaceuticals’ Stock is Going to Recover

In a report released yesterday, Michael Okunewitch from Maxim Group initiated coverage with a Buy rating on Citius Pharmaceuticals (CTXR – Research Report) and a price target of $4.00. The company's shares closed last Wednesday at $1.62, close to its 52-week low of $1.31. According to TipRanks.com, Okunewitch is a 1-star analyst with an average return of -15.3% and a 16.7% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Kiora Pharmaceuticals, ATAI Life Sciences, and SeqLL. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Citius Pharmaceuticals with a $6.67 average price target, representing a 304.2% upside.

Howard Kim on TipRanks | February 16, 2022

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Study May Proceed letter for Halo-Lido for the treatment of hemorrhoids. The Company is a

Yahoo | February 15, 2022

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today reported business and financial results for the first fiscal quarter of 2022 ended December 31, 2021.

Yahoo | February 10, 2022

Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX), Oramed Pharmaceuticals (ORMP) and Citius Pharmaceuticals (CTXR)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTX – Research Report), Oramed Pharmaceuticals (ORMP – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments. Repare Therapeutics (RPTX) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics, with a price target of $54.00. The company's shares closed last Friday at $15.23, close to its 52-week low of $13.97. According to TipRanks.

Brian Anderson on TipRanks | January 18, 2022

Citius Pharmaceuticals (CTXR) Receives a Buy from Dawson James

In a report issued on December 6, Jason Kolbert from Dawson James maintained a Buy rating on Citius Pharmaceuticals (CTXR – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $1.69. According to TipRanks.com, Kolbert is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Sorrento Therapeutics, and Anavex Life Sciences. Citius Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.00, representing a 311.8% upside.

Brian Anderson on TipRanks | January 5, 2022

Read More 'CTXR' Stories Here

CTXR Price Returns

1-mo -1.11%
3-mo -42.31%
6-mo -46.43%
1-year -61.21%
3-year -30.23%
5-year -86.30%
YTD -41.56%
2021 50.98%
2020 0.00%
2019 -1.92%
2018 -72.63%
2017 -42.94%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0095 seconds.